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SUMMARY
Most colorectal cancer (CRC)-related deaths are
due to liver metastases. PKCz is a tumor suppres-
sor in CRC with reduced expression in metastasis.
Given the importance of microRNAs (miRNAs) in
regulating cellular plasticity, we performed an unbi-
ased screening and identified the miR-200 family as
the most relevant miRNAs downregulated by PKCz
deficiency. The regulation of the intracellular levels
of miR-200 by PKCz is post-transcriptional and
involves their secretion in extracellular vesicles.
Here, we identified ADAR2 as a direct substrate
of PKCz in CRC cells. Phosphorylation of ADAR2
regulates its editing activity, which is required to
maintain miR-200 steady-state levels, suggesting
that the PKCz/ADAR2 axis regulates miR-200
secretion through RNA editing. Loss of this axis re-
sults in epithelial-to-mesenchymal transition (EMT)
and increased liver metastases, which can be in-
hibited in vivo by blocking miR-200 release. There-
fore, the PKCz/ADAR2 axis is a critical regulator of
CRC metastases through modulation of miR-200
levels.
INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer diag-
nosed in the United States and ranks third in cancer-related
deaths (Siegel et al., 2016). The main cause of death in patients
with CRC is liver metastasis, with nearly 70% of CRC patients
eventually developing a liver tumor (Mehlen and Puisieux,
2006). Moreover, metastasis accounts for more than 90% of all
deaths in cancer patients (Mehlen and Puisieux, 2006). Recent
evidence has demonstrated that plasticity is a key feature of
metastatic cells, and that microRNAs (miRNAs) are important
in regulating the tumor phenotype as it transitions from a benign
adenoma, with epithelial characteristics, to an invasive tumor
with mesenchymal and stem-cell-like properties (Pencheva
and Tavazoie, 2013). The emergence of a consensus molecular
subtyping for CRC has revealed that the stem-like/mesenchymal
CRC subtype is associatedwith poor prognosis, aggressive can-
cer, and dysregulation of miRNAs (Guinney et al., 2015). Thus,
understanding the mechanisms controlling the expression of
miRNAs has emerged as a potential venue for the design of bet-
ter strategies to treat metastasis.
Our laboratory recently identified protein kinase C z (PKCz) as
a tumor suppressor in CRC. PKCz (encoded by thePRKCZ gene)
is under-expressed in human CRC relative to normal colon tis-
sue, and its levels are also considerably decreased in distant
metastasis, which correlates with poor prognosis (Ma et al.,
2013). In addition, cancer-associated loss-of-function mutations
were found in the kinase domain of PKCz, implicating the impor-
tance of the kinase activity for its role as a tumor suppressor
(Galvez et al., 2009; Ma et al., 2013). One possibility when target-
ing tumor suppressors as therapeutic targets is to deviseways to
restore their levels or activity. This can be challenging, and an
alternative approach is to elucidate their mechanisms of action
to identify cell vulnerabilities created by the loss of the tumor
suppressor’s function. This is the rationale for investigating the
signaling pathways unleashed during PKCz inactivation in can-
cer. In this regard, our previous studies demonstrated that
the loss of PKCz allows the metabolic reprogramming of CRC
cells under conditions of nutrient stress to promote cancer cell
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survival and tumorigenesis (Ma et al., 2013). Likewise, our data
also demonstrated that PKCz is a repressor of the b-catenin
and Yap pathways in intestinal stem cells, which is important
for intestinal regeneration and cancer (Llado et al., 2015). How-
ever, both types of signaling cascades are difficult to target,
and key potential points of intervention need to be found.
Whether PKCz is not only involved in the repression of tumor initi-
ation and survival but also restrains metastasis through the regu-
lation of the expression of miRNAs has not yet been explored.
Here, we show that PKCz exerts its metastasis suppressor activ-
ity via activation of the RNA editing enzyme adenosine deami-
nases acting on RNA 2 (ADAR2), which regulates the intracellular
levels of the miR-200 family of miRNAs.
RESULTS
Loss of PKCz Is Associated with Decreased Expression
of the miR-200 Family
Considering the importance of miRNAs in intestinal carcinogen-
esis, we explored whether the loss of PKCzmay lead to changes
in the miRNA expression profile of CRC cells. To this effect,
SW480 human CRC cells were infected with lentiviruses ex-
pressing short hairpin non-targeting (shNT) or shRNA selective
for PKCz (shPKCz), and microarrays were used to create global
gene-expression profiles of both mRNAs and miRNAs (GEO:
GSE42186; Table S1). From this analysis, we found a list of 74
miRNAs that significantly changed in shPKCz cells (Figure 1A).
In parallel, we also analyzed the mRNA expression levels of
shNT and shPKCz cells and performed gene set enrichment
analysis (GSEA) using the ‘‘C3 miRNA target motifs’’ gene set
compilation to predict whichmiRNAs were active/inactive based
on 30 UTR miRNA-binding motifs present in mRNAs that were
differentially expressed in shPKCz cells (Figures 1A and S1A).
To select the most biologically relevant miRNAs altered by
PKCz loss, we crossed these data with a profile of human
miRNAs that were significantly changed in CRC patients with
low PRKCZ mRNA expression as compared to those with high
PRKCZ levels. To do that, we used The Cancer Genome Atlas
network colon adenocarcinoma dataset (TCGA-COAD) and
selected patients in the top and bottom 25% of PRKCZ mRNA
expression levels. We then identified the miRNAs and mRNAs
that were significantly altered in both groups and subjected
them to GSEA using the ‘‘C3 miRNA target motifs’’ gene matrix
(Figures 1A and S1A). Finally, we crossed the results from the
analysis of the miRNA profile in shPKCz cells with those of the
human TCGA-COAD, which converged in the identification of
miR-200b, miR-200c, andmiR-429 as themost relevant miRNAs
significantly downregulated under conditions of PKCz deficiency
(Figure S1B). The miRNAs identified in our unbiased approach
are part of the miR-200 family, which consists of five evolution-
arily conserved miRNAs (miR-200b, miR-200a, miR-429, miR-
200c, and miR-141) that are localized in two polycistronic
clusters: miR-200b/200a/429 on chromosome 1, and miR-
200c/141 on chromosome 12 (Figure S1C). They share a high de-
gree of sequence homology, with a difference of only 1 nt in their
seed sequence: miR-141/200a (seed AACACUG) andmiR-200b/
200c/429 (seed AAUACUG). Importantly, the miR-200 family
members have been described as key players in mediating
stemness and epithelial-to-mesenchymal transition (EMT), pro-
cesses that reportedly facilitate tumor metastasis (Hur et al.,
2013; Wellner et al., 2009). Accordingly, we focused our efforts
on this subset of miRNAs.
Because PKCz is a tumor suppressor in intestinal cancer
(Llado et al., 2015; Ma et al., 2013), we hypothesized that the
downregulation of miR-200s could contribute to its tumor sup-
pressor role. To start exploring this possibility, we first validated
the findings of the miRNA profiling by measuring the expression
levels of miR-200s by qPCR in shNT and shPKCz cells. There
was a significant downregulation of all the members of the
miR-200 family in shPKCz cells, with no changes in the levels
of two unrelated miRNAs (miR-16-5p and miR-26a-5p) (Fig-
ure 1B). Similar results were obtained in the humanCRC cell lines
RKO and HCT116 (Figures S1D and S1E). Importantly, miR-
200s, but not miR-16-5p, were also decreased in SW620 cells,
a metastatic derivative from the same patient from which
SW480 cells were derived and a CRC line expressing lower
endogenous PKCz levels (Figure 1C). We also noted a similar
altered expression profile in intestinal organoids from PKCz
knockout (KO) mice (Figure 1D).
Lgr5+ intestinal stem cells (ISCs) are believed to be the cells of
origin of intestinal cancer, and have recently been shown to be
critical for CRC liver metastasis (Barker et al., 2007; de Sousa
e Melo et al., 2017). This is noteworthy because PKCz has
been shown to regulate ISC function and tumorigenesis (Llado
et al., 2015). Functional activity of ISCs can be measured by in-
testinal regeneration after acute damage, as modeled by irradia-
tion (IR)-induced ablation of the intestinal epithelium (Llado et al.,
2015). To this end, we monitored the levels of miR-200s in KO
mice for PKCz, looking specifically in the Lgr5+ ISC population
(Lgr5;PKCzf/f) post IR. Interestingly, reduced levels of miR-
200s upon PKCz deficiency were concomitant with higher repo-
pulation activity in Lgr5;PKCzf/f ISCs (Llado et al., 2015) (Fig-
ure 1E). Furthermore, our previous data demonstrated that the
selective loss of PKCz in Lgr5+ ISCs deficient for APC enhanced
the tumor-forming potential and stem activity of these cells
(Llado et al., 2015). Analysis of miR-200s in organoids derived
from the intestinal tumors of these mice also revealed significant
downregulation of these miRNAs in PKCz-deficient organoids
(Figure 1F). These data validated our findings from the miRNA
profile and support the notion that downregulation of miR-200
family members might be a functionally important downstream
event upon PKCz loss.
Aberrant regulation of miR-200 family members has been re-
ported to be associated with tumor progression, metastasis,
and drug resistance in several types of cancers, including CRC
(Diaz et al., 2014; Hur et al., 2013). In particular, high levels
of miR-200a, miR-200c, and miR-429 have been shown to
correlate with increased overall survival in CRC patients with
stage I–III cancer (Diaz et al., 2014). Moreover, levels of miR-
200s have been proposed as prognostic markers to predict
beneficial response to adjuvant chemotherapy in CRC patients
(Diaz et al., 2014). Notably, miR-200c andmiR-200b were down-
regulated at the invasive front of CRC tumors but upregulated
in metastases. Our bioinformatics analysis of TCGA-COAD re-
vealed that low expression of the miR-200b/a family members
correlated with a worse patient prognosis in terms of overall
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survival and relapse (Figures 1G and S1F). More importantly, we
found a significant positive correlation between PRKCZ mRNA
levels and those of the miR-200b/a/429 cluster in the same hu-
man CRC dataset (Figure 1H). These results support our hypoth-
esis that downregulation of miR-200s occurs upon PKCz loss,
and that this could be a critical event in intestinal carcinogenesis,
not only in mice but also in human patients.
Loss of PKCz Promotes EMT through the Regulation of
miR-200 Levels
Because low expression of the miR-200 family members has
been reported to promote the acquisition of stem cell properties
and to induce EMT in tumor cells, we next determined the impact
that PKCz regulation of miR-200s has on the mRNA expression
levels of markers of stemness and EMT in shNT and shPKCz
Figure 1. miR-200s Positively Correlate with PKCz in Colorectal Cancer
(A) Venn diagram of common miRNAs identified from an miRNA microarray using SW480 cells, TCGA colon adenocarcinoma miRNA expression profile, and
GSEA-C3 analysis of the mRNAs from the datasets.
(B–F) qPCR of miRNAs and immunoblot of PKCz in SW480 shNT and shPKCz cells, n = 4 biological replicates (B); SW480 and SW620 cells, n = 4 biological
replicates (C); WT and PKCz/ mouse intestinal organoids, n = 3 biological replicates (D); ileum tissue 3 days post irradiation from Lgr5 and Lgr5;PKCzf/f mice,
n = 3 mice/group (E); and intestinal tumor organoids from Lgr5;APCf/f and Lgr5;PKCzf/fAPCf/f mice, n = 3 biological replicates (F).
(G) Kaplan-Meier overall survival analysis of TCGA colon adenocarcinoma patients.
(H) Correlation between PRKCZ gene expression and the miR-200b/a/429 cluster in TCGA colon adenocarcinoma patients; n = 233 patients.
Results are presented as mean ± SD. **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S1 and Table S1.
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cells. Consistent with a critical role of PKCz in miR-200 regula-
tion, we found that shPKCz cells displayed reduced epithelial
markers with a concomitant increase in mesenchymal markers
(Figure 2A). Similarly, loss of PKCz resulted in the increased
expression of genes associated with intestinal stemness (Fig-
ure 2A). Immunoblot analysis confirmed the reduced levels of
E-cadherin concomitant with a gain in Zeb1, TGFb, and CD44
in shPKCz cells (Figure 2B). In keeping with these results,
Figure 2. Loss of PKCz Promotes EMT through miR-200s
(A) qPCR of epithelial, mesenchymal, and stem-like genes in SW480 shNT and shPKCz cells; n = 3 biological replicates.
(B) Immunoblot of EMT markers in SW480 shNT and shPKCz cells; n = 3 biological replicates.
(C) Representative pictures of cell morphology of SW480 shNT and shPKCz cells. Scale bar, 50 mm.
(D) GSEA plot of EMT, extracellular matrix remodeling, and stem-like signatures in low- versus high-PRKCZ-expressing tumors from TCGA-COAD. FDR, false
discovery rate; NES, normalized enrichment score.
(E) Immunofluorescence for E-cadherin (left) and quantification of E-cadherin intensity (right) in SW480 shNT, shPKCz, and shPKCz cells rescued with miR-200a/
b. Scale bar, 20 mm; n = 3 biological replicates.
(F) Immunofluorescence for Zeb1 (left) and quantification of Zeb1 intensity (right) in SW480 shNT, shPKCz, and shPKCz cells rescuedwithmiR-200a/b. Scale bar,
20 mm; n = 3 biological replicates.
(G) qPCR of mesenchymal genes (left) and immunoblot of PKCz (right) in SW480 shNT, shPKCz, and shPKCz cells rescued with miR-200a/b; n = 3 biological
replicates.
(H) Representative pictures of cell morphology of SW480 shPKCz cells rescued with miR-200a/b. Scale bar, 50 mm.
(I) Summary of the correlation between PRKCZ gene neighbors and CRC gene set signatures.
Results are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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PKCz knockdown induced a more mesenchymal morphology
(Figure 2C). Importantly, these in vitro results were corroborated
in patients by GSEA using TCGA-COAD, which established that
PRKCZ expression negatively associates with EMT and stem-
ness in human CRC patients (Figure 2D). These results strongly
support a model whereby PKCz deficiency promotes stemness
and a more mesenchymal phenotype in CRC cells, through a
mechanism that involves the control of the levels of miR-200s.
In agreement with this, the mesenchymal characteristics of
shPKCz cells were severely abrogated when the levels of miR-
200a/b were restored by the overexpression of miR-200a/b
mimics. Indeed, immunofluorescence analysis revealed that
the overexpression of miR-200a/b mimics rescued the loss of
the epithelial marker E-cadherin (Figure 2E) and decreased the
gain of the mesenchymal marker Zeb1 (Figure 2F). In association
with these changes, we confirmed a decrease in mesenchymal
transcripts (Figure 2G) and an increase in epithelial morphology
(Figure 2H). These results establish that PKCz is an important
regulator of EMT through its ability to modulate the levels of
miR-200s. These results are also relevant from the clinical point
of view, becausemultiple studies have linked EMT and stemness
with a poor-prognosis subtype in CRC patients (Guinney et al.,
2015; Marisa et al., 2013; Sadanandam et al., 2013). Interest-
ingly, when gene neighbors of PRKCZ were compared with the
molecular signatures of three separate studies of CRC patients,
we found that transcripts associated with PRKCZ expression
negatively correlated with the EMT/stemness and poor-prog-
nosis CRC patient groups (Figure 2I).
PKCz Regulates the Steady-State Level of miR-200s
We next investigated the mechanism whereby PKCz deficiency
leads to reduced intracellular levels of miR-200s. We first deter-
mined whether the expression of this subset of miRNAs was
regulated transcriptionally or post-transcriptionally. miR-200b,
miR-200a, andmiR-429 are located in a single polycistronic tran-
script (Figure S2A). qPCR of the region encoding the primary
miRNAs in this cluster revealed no significant alterations in the
transcription of these miRNAs (Figure S2B). Furthermore, exper-
iments using the full-length endogenous promoter of the miR-
200b/a/429 cluster tagged with luciferase revealed no change
in the transcription of this cluster when PKCz was knocked
down (Figure S2C), suggesting that the loss of PKCz is most
likely affecting the levels of miR-200s post-transcriptionally. No
changes in the levels of the components of the RNA-induced
silencing complex (RISC) were observed (Figures S2D–S2G).
Although we did not detect alterations in the pri-miRNA, north-
ern blot analysis demonstrated a drastic reduction in the levels of
mature miR-200b-3p and miR-200c-3p in shPKCz cells despite
the lack of changes in the precursor form (Figure 3A). No defect
was observed in the nuclear export of pre-miR-200b (Figure 3B).
Figure 3. PKCz Regulates the Steady-State Levels of the miR-200 Family
(A) Northern blot of precursor and mature miR-200b in SW480 shNT and shPKCz cells (left) and quantification of band intensities (right). U6 small nuclear RNA
(snRNA), loading control; n = 3 biological replicates.
(B) Northern blot of precursor and mature miR-200b from nuclear and cytosolic fractions of SW480 shNT and shPKCz cells (left) and quantification of band
intensities, relative to U6 (nuclear) and tRNA (cytoplasmic) (right); n = 3 biological replicates.
(C) Northern blot from an in vitro precursor-processing reaction of miR-200b using SW480 shNT and shPKCz cell lysates; n = 3 biological replicates.
(D) qPCR of miRNAs (left) and immunoblot of PKCz levels (right) in SW480 shNT and shPKCz cells after 10 mg/mL actinomycin D treatment for the indicated time
points; n = 3 biological replicates.
Results are presented as mean ± SD. *p < 0.05, **p < 0.01, ****p < 0.0001. See also Figure S2.
1182 Cell Reports 23, 1178–1191, April 24, 2018
Figure 4. PKCz Regulates the Secretion of miR-200s in EVs
(A–C) qPCR of extracellular miRNAs from SW480 shNT and shPKCz cells, n = 4 biological replicates (A); SW480 and SW620 cells, n = 3 biological replicates (B);
and intestinal tumor organoids from Lgr5;APCf/f and Lgr5;PKCzf/fAPCf/f mice, n = 3 biological replicates (C).
(D) qPCR of extracellular miRNAs from SW480 shNT and shPKCz cells treated with vehicle control or 10 mM GW4869; n = 3 biological replicates.
(E) qPCR of intracellular miRNAs (left) and immunoblot of PKCz (right) from SW480 shNT and shPKCz cells treated with vehicle control or 10 mM GW4869; n = 4
biological replicates.
(F) qPCR of intracellular miRNAs (left) and immunoblot of Rab27a and PKCz (right) fromSW480 shNT and shPKCz cells treatedwith 50 nM siRNA against Rab27a;
n = 4 biological replicates.
(G) qPCR of miRNAs in total EVs from SW480 shNT, shPKCz, and shPKCz cells treated with vehicle control or 10 mM GW4869; n = 3 biological replicates.
(H) Size and concentration measurements of EVs from SW480 cells prepared by ultracentrifugation (UC) or ExoQuick; n = 3 biological replicates.
(I) Immunoblot of intracellular and EV markers in whole-cell lysates (WCL) and EVs from HCT116 shNT and shPKCz cells; n = 2 biological replicates.
(legend continued on next page)
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Furthermore, results from an in vitro precursor-processing assay
showed no defects in shPKCz lysates for the generation of
mature miR-200b (Figure 3C). All this, coupled with the fact
that the decrease in mature miR-200b-3p in shPKCz cells does
not correlate with increased levels of pre-miR-200b (Figure 3A),
strongly suggests that PKCz is most likely affecting the steady-
state levels of mature miR-200s rather than processing. To test
this possibility, we treated shNT and shPKCz cells with the tran-
scriptional inhibitor actinomycin D and compared the levels of
endogenous mature miR-200s (Figure 3D). After inhibiting
de novo transcription of RNA, the steady-state levels of mature
miR-200s decreased more rapidly in shPKCz than in shNT cells
(Figure 3D). No difference in the steady-state levels of miR-16-5p
between the genotypes was observed (Figure 3D). These results
demonstrate that PKCz deficiency does not affect the synthesis
or maturation of miR-200s but targets a step regulating the
maintenance of their steady-state levels.
PKCz Regulates the Secretion of miR-200s
We next hypothesized that PKCz deficiency might lead to
decreased intracellular levels of miR-200s by promoting their
secretion. In support of this possibility, we observed increased
levels of miR-200s, but not miR-26a-5p, in the conditioned me-
dia from shPKCz cells (Figure 4A), SW620 cells as compared
to SW480 (Figure 4B), and PKCz-deficient organoids (Figure 4C).
Previous reports of miRNAs secreted via multivesicular bodies
(MVBs) have demonstrated that they are present in extra-
cellular vesicles (EVs) termed exosomes (Gibbings et al., 2009;
McKenzie et al., 2016). When shNT and shPKCz cells were
treated with a chemical inhibitor of neutral sphingomyelinases,
GW4869, which has been reported to be required for the release
of EVs fromMVBs (Kosaka et al., 2010; Trajkovic et al., 2008), we
observed that the increased levels of miR-200s in the extra-
cellular milieu of shPKCz cells were reduced to control levels
(Figure 4D). Importantly, the reduced intracellular levels of miR-
200s in shPKCz cells were rescued by the addition of GW4869
(Figure 4E). No decrease in cell viability or proliferation was
observed in response to GW4869 treatment (Figures S3A and
S3B). Likewise, knockdown of Rab27a, which is also required
for the secretory machinery by promoting the docking of MVBs
to the plasma membrane (Ostrowski et al., 2010), rescued the
reduced intracellular levels of miR-200s in shPKCz cells (Fig-
ure 4F). Consistent with miR-200s being secreted in EVs, we
found significantly more miR-200s in EVs from shPKCz cells
than in shNT cells, which were inhibited by blocking secretion
with GW4869 (Figure 4G). Nanoparticle tracking analysis (NTA)
revealed that EVs prepared by two different methods had a
size of approximately 100–150 nm, which is consistent with
that of exosomes (Figures 4H and S3C). Of note, no changes
were found in vesicle concentration in shPKCz as compared to
shNT cells (Figures 4H and S3C). In addition, immunoblot anal-
ysis of these vesicles confirmed the presence of exosome-en-
riched proteins, including the tetraspanin CD63 and members
of the endosomal sorting complexes required for transport
(TSG101, Flotillin-1, and Alix), as well as the absence of intracel-
lular proteins, such as peroxiredoxin 3 and histone 3 (Figures 4I
and S3D). Furthermore, increased levels of miR-200s were also
observed in CD63+ EVs purified from shPKCz cells as compared
to those from shNT cells (Figures 4J and S3E). Efficient pull-
down of CD63 was confirmed by western blot (Figure S3F).
NTA and transmission electron microscopy (TEM) of purified
CD63+ EVs showed sizes compatible with exosomes (Figures
4K and 4L). These results establish that the increased secretion
of miR-200s by shPKCz cells is through exosomes via MVBs.
Because no differences were found in the amount of EVs
secreted by shPKCz as compared to that in shNT cells (Figures
4H and S4C), our results suggest that the higher secreted levels
of miR-200s by PKCz-deficient cells are most likely due to
increased loading, rather than increased secretion of EVs.
Loss of PKCz Promotes Liver Metastasis through
Secretion of miR-200s
In agreement with the connection of EMT/stemness with inva-
sion and metastasis, we observed that shPKCz cells displayed
increased cell migration and invasion in vitro (Figure 5A). There-
fore, we next investigated whether the loss of PKCz could trigger
a metastatic phenotype in CRC cells in vivo. Liver metastases
were induced in immunodeficient mice by in vivo intrasplenic
injection of SW480 shNT or shPKCz cells followed by
splenectomy, after which metastatic colonization was analyzed
28 days thereafter (Figure 5B). Mice injected with shPKCz cells
displayed higher liver metastasis burden and increased metas-
tasis area than those injected with shNT cells (Figures 5C–5F).
A quantitative analysis measuring human Alu sequences in the
mouse liver confirmed these conclusions (Figure 5G). These re-
sults establish that PKCz deficiency confers CRC cells with a
metastatic phenotype. Because our model predicts that this
is through the loading of miR-200s into exosomes, we next
determined whether metastatic CRC patients had higher levels
of miR-200s in EVs from their plasma. Notably, we found that
plasma CD63+ EVs from CRC metastatic patients displayed
higher levels of miR-200b-3p, but not of the unrelated miR-
26a-5p, than those from non-metastatic CRC patients (Fig-
ure 5H). In order to determine the potential involvement of
exosomes in the liver metastatic phenotype of PKCz-deficient
CRC cells, we repeated the intrasplenic model as above
but included the treatment of mice for the first 5 days with
GW4869 or DMSO, as a negative control (Figure 5I). Interest-
ingly, GW4869-treatedmice displayed reducedmetastatic activ-
ity of shPKCz cells that became comparable to that of shNT
levels (Figures 5J–5N). As a readout of miR-200s, we analyzed
the EMT phenotype in the liver metastases of this experiment.
Importantly, the liver metastases induced by PKCz-deficient
cells displayed an EMT phenotype with loss of E-cadherin and
(J and K) qPCR ofmiRNAs in CD63+ EVs and immunoblot of CD63 after CD63 pull-down, n = 4 biological replicates (J), and size and concentrationmeasurements
of CD63+ EVs, n = 3 biological replicates (K), from SW480 shNT and shPKCz cells.
(L) TEM of EVs from shNT and shPKCz cells. Scale bars, 0.1 mm.
Results are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S3.
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gain of vimentin that was reverted byGW4869 treatment (Figures
5O–5Q). Altogether, these results demonstrate that PKCz re-
presses the metastatic potential of CRC cells by controlling the
intracellular steady-state levels of miR-200s through the regula-
tion of their secretion.
PKCz Phosphorylates and Activates ADAR2 to Promote
the Accumulation of miR-200s
To explore how PKCz specifically regulates the levels of mature
miR-200s, we tested whether its kinase activity was required for
that function. Thus, we reconstituted wild-type (WT) or a kinase-
dead (KD) mutant of PKCz into shPKCz cells. Importantly, the
expression of WT-PKCz, but not the KD-PKCz mutant, was
able to rescue the levels of the miR-200 family (Figure 6A). Given
that PKCz’s kinase activity is required for that effect, we then car-
ried out an unbiased screening for PKCz substrates in SW480
cells stably expressing WT-PKCz or its analog-sensitive (AS)
PKCzmutant, which utilizes a bulky ATP analog (benzyl-ATPgS)
that cannot be used by endogenous kinases and transfers
a thiophosphate onto its substrates (Figure S4A). Among the
identified putative substrates, we selected ADAR2 for further
analysis based on two criteria: (1) proteins involved in miRNA
regulation; and (2) proteins known to regulate cell migration.
ADAR2 is an enzyme that edits adenosine to inosine (A-to-I) nu-
cleotides in RNA (Kawahara et al., 2007). An in vitro phosphory-
lation assay using recombinant PKCz confirmed that ADAR2 is a
bona fide PKCz substrate (Figure 6B). In addition, we established
that PKCz interacts with ADAR2 in reciprocal co-transfection
(Figures 6C and 6D) and in semi-endogenous (Figures 6E
and 6F) experiments and, more importantly, in endogenous
conditions (Figure 6G).
Next, we investigated whether ADAR2 played a functional
role in the secretion of the miR-200s and, consequently, the
EMT phenotype. Upon knockdown of ADAR2, we observed a
decrease in the intracellular levels of the miR-200s, concomitant
with their increased secretion in CD63+ EVs (Figures 6H and 6I).
No changes were observed in the size or concentration of the
secreted vesicles (Figure S4B). Consistent with the loss of intra-
cellular miR-200 levels, ADAR2-deficient cells had decreased
expression of epithelial genes and increased expression of
mesenchymal genes, both at mRNA and protein levels, as well
as an enhanced mesenchymal morphology (Figures 6J–6L).
The EMT phenotype upon ADAR2 deficiency was also observed
by immunofluorescence of E-cadherin and Zeb1 (Figures 6M
and S4C). Importantly, the overexpression of miR-200a/b
mimics reversed the mesenchymal transition observed in
ADAR2-deficient cells (Figure S4D). Similar to PKCz-deficient
cells, the loss of ADAR2 also induced increased migration and
invasion (Figure 6N). These results demonstrate that ADAR2 is
required for maintaining the intracellular levels of miR-200s and
the epithelial morphology of CRC cells, and that ADAR2 loss
recapitulates the phenotype of PKCz-deficient cells.
ADAR2 is known to undergo self-editing of its own pre-mRNA
to create an alternative splice site within intron 1, leading to the
inclusion of 47 extra nucleotides that produces a frameshift in
the coding region and results in a truncated, inactive protein
(Rueter et al., 1999) (Figure 6O). In this way, ADAR2 controls its
own activity by self-regulating its own mRNA and protein levels.
Therefore, reduced levels of self-editing mRNA that results in
increased ADAR2 protein levels are surrogate markers of in-
hibited ADAR2 activity. We hypothesized that PKCz might be
required for the activation of ADAR2. Consistent with this notion,
we found lower levels of the self-editing product in intestinal
organoids fromPKCzKOmice, and in SW480 shPKCz cells, rela-
tive to their respective controls, demonstrating that PKCz phos-
phorylation is critical for the maintenance of ADAR2 gene editing
activity (Figure 6P). In agreement with this, we found that ADAR2
mRNA and protein levels were increased in shPKCz cells (Fig-
ures S4E and S4F), as well as that ADAR2 protein levels were
higher in tumors from Lgr5;PKCzf/fAPCf/f mice as compared to
Lgr5;APCf/f (Figure S4G).
Liquid chromatography-tandem mass spectrometry (LC-
MS/MS) analysis identified serines 211 and 216 as the targets
of PKCz phosphorylation on ADAR2 (Figure S4H), which are
conserved across different species (Figure S4I). These residues
lie between the two protein double-stranded RNA-bindingmotifs
(DRBM1 and DRBM2; Figure 6Q), which are important domains
for ADAR2 activity (Sansam et al., 2003), suggesting that phos-
phorylation of these residues by PKCz may regulate ADAR2
activity. To determine the role of ADAR2 phosphorylation by
PKCz, we mutated these serine residues to alanine to create
ADAR2SS211/216AA and confirmed that these were the amino
acids phosphorylated by PKCz using an in vitro kinase assay
with purified proteins (Figure 6R). Importantly, expression
of ADAR2SS211/216AA, but not ADAR2WT, in SW480 cells
significantly decreased miR-200 levels, comparable to that
produced by the expression of an enzymatically inactive form
of ADAR2 (ADAR2E396A) that lacks RNA editing capacity (Fig-
ure 6S). Furthermore, incubation of SW480 cells expressing
ADAR2SS211/216AA or ADAR2E396A with actinomycin D showed
Figure 5. Loss of PKCz Promotes Liver Metastasis
(A) Cell migration and invasion assay (left) and immunoblot of PKCz (right) in SW480 shNT and shPKCz cells; n = 3 biological replicates.
(B–G) Experimental design for liver metastases and immunoblot of PKCz (B) in SW480 shNT and shPKCz cells used for splenic injection (n = 8 mice per group);
bioluminescence imaging and liver photographs; scale bar, 1 cm (C); quantification of total photon counts (shNT, n = 7; shPKCz, n = 8) (D); H&E staining of liver
sections; scale bar, 200 mm (E); quantification of metastatic area relative to total liver area (F); and quantification of humanmetastases in mouse liver by qPCR (G).
(H) qPCR of miRNAs in exosomes from plasma of non-metastatic (n = 8) and metastatic (n = 6) patients.
(I–N) Experimental design for inhibiting CRC liver metastases with GW4869 and immunoblot of PKCz (I) in SW480 shNT and shPKCz cells used for splenic
injection; bioluminescence imaging and liver photographs of mice injected with SW480 shNT (n = 4), shPKCz (n = 4), or shPKCz cells + GW4869 (n = 5); scale bar,
1 cm (J); quantification of total photon counts (K); H&E staining of liver sections; scale bar, 200 mm (L); quantification of humanmetastases in mouse liver by qPCR
(M); and quantification of metastatic area relative to total liver area (N).
(O–Q) Immunofluorescence for E-cadherin and vimentin of liver metastases of the experiment described in (I) (n = 3); scale bars, 50 mm (O). Quantification of
E-cadherin (P) and vimentin (Q) areas.
Results are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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that the levels of endogenous mature miR-200s, but not those of
miR-16-5p, were reduced more rapidly in mutant ADAR2-ex-
pressing cells than in ADAR2WT cells (Figure S4J). These results
demonstrate that the activation of ADAR2 by PKCz phosphory-
lation is a key mechanism for the regulation of the steady-state
levels of miR-200s.
Consistent with PKCz phosphorylation mediating ADAR2
activity, we observed hypo-editing of coatamer protein alpha
(COPA), which has previously been reported to be a substrate
of ADAR2 and to be hypo-edited in cancer (Chan et al., 2014).
PKCz-deficient cells displayed reduced COPA editing, which
could be rescued by reconstituting SW480 shPKCz cells with
WT-PKCz (Figure 6T). Similarly, COPA editing was significantly
reduced in cells deficient in ADAR2, as well as in cells expressing
the phospho-dead mutant ADAR2SS211/216AA or the catalytically
inactive mutant ADAR2E396A (Figure 6T). Hypo-editing of COPA
could also be confirmed in SW620 cells, which have reduced
levels of endogenous PKCz (Figure 6T). Moreover, COPA was
found to be significantly hypo-edited in tumors from human
CRC patients, relative to adjacent normal tissue from the same
patients, and the editing levels were consistent with what was
observed in vitro (Figure S4K). Consequently, this suggests
that phosphorylation of ADAR2 by PKCz is required for its activ-
ity, which is necessary for the regulation of the intracellular levels
of miR-200s.
DISCUSSION
Here, we demonstrate that the loss of PKCz in CRC cells is asso-
ciated with lower ADAR2 activity, which promotes the loading of
miR-200s into EVs, thereby decreasing their intracellular steady-
state levels. This reduced PKCz/ADAR2/miR-200 signaling
pathway gives rise to an EMT/stemness phenotype, which ex-
plains the higher metastatic activity of PKCz-deficient CRC cells.
This is an unexpected mechanism for the regulation of miR-200s
that has important repercussions in vivo because, as shown
here, CRC patients with metastatic tumors have increased
serum levels of exosomes containing miR-200s, indicating a
potential non-invasive diagnostic marker for patients at risk of
metastasis. We also demonstrate that the pharmacological inhi-
bition of miR-200 secretion in vivo severely impairs CRC metas-
tasis to the liver. This is of great potential therapeutic relevance,
because it constitutes a proof of concept that targeting PKCz
downstream signals activated upon its loss of function can be
useful anti-metastatic therapies.
The inhibition of ADAR2 activity upon loss of PKCz as a mech-
anism for tumor invasiveness is a key finding for CRC, and is
consistent with previous reports for ADAR2 acting as a tumor
suppressor in other types of neoplasia. Most notably, ADAR2 ed-
iting activity has been shown to inhibit the growth and migration
of astrocytomas, with decreased editing of the ionotropic gluta-
mate receptors GluR-B and GluR-6, and the cell-cycle-regu-
lating phosphatase CDC14B being implicated as a potential
driver of the disease (Cenci et al., 2008; Galeano et al., 2013).
However, the hypo-editing of these substrates is unlikely to be
involved in the context of PKCz-deficient CRC cells, considering
that the ionotropic glutamate receptors are restricted to the
central nervous system, and CRC cells deficient for PKCz
do not exhibit increased proliferation (Figure S3B). Importantly,
ADAR2 has also been reported to be tumor suppressive in other
solid tumors, such as gastric cancer, hepatocellular carcinoma,
and esophageal squamous cell carcinoma (Chan et al., 2014,
2016; Chen et al., 2017), which underscores the importance of
ADAR2 beyond CRC. Yet, despite being implicated as a tumor
suppressor, little is known about the regulation of ADAR2 in can-
cers. In fact, although the phosphorylation of residues S26, S31,
and T32 has been previously reported to regulate ADAR2 activity
through a mechanism involving Pin1, a kinase was not identified
in that study (Marcucci et al., 2011). Given the role that ADAR2
plays in inhibiting multiple types of cancer, our finding that
Figure 6. PKCz Phosphorylates and Regulates ADAR2 Activity
(A) qPCR of miR-200s (left) and immunoblot of PKCz (right) in SW480 shNT and shPKCz cells reconstituted with HA-PKCzWT or HA-PKCzKD; n = 4 biological
replicates. HA, hemagglutinin.
(B) Immunoblot of in vitro phosphorylation reaction for ADAR2 and PKCz; n = 3 biological replicates. GST, glutathione S-transferase.
(C and D) Reciprocal co-immunoprecipitation of GST-ADAR2 and Flag-PKCz, IP anti-Flag (C) and anti-GST (D); n = 3 biological replicates.
(E and F) Reciprocal semi-endogenous co-immunoprecipitation of Flag-ADAR2 and PKCz, IP anti-Flag (E) and anti-PKCz (F); n = 2 biological replicates.
(G) Endogenous co-immunoprecipitation of PKCz and ADAR2; n = 2 biological replicates.
(H) qPCR of miRNAs (left) and immunoblot of ADAR2 (right) in SW480 shNT and shADAR2 cells; n = 3 biological replicates.
(I) qPCR of miRNAs in CD63+ EVs from SW480 shNT and shADAR2 cell media; n = 4 biological replicates.
(J) qPCR of epithelial (left) and mesenchymal genes (right) in SW480 shNT and shADAR2 cells; n = 3 biological replicates.
(K) Immunoblot of EMT markers in SW480 shNT and shADAR2 cells; n = 3 biological replicates.
(L) Representative pictures of the cell morphology of SW480 shNT and shADAR2 cells. Scale bar, 50 mm.
(M) Immunofluorescence for E-cadherin (left) and quantification of E-cadherin intensity (right) in SW480 shNT and shADAR2 cells. Scale bar, 20 mm; n = 3
biological replicates.
(N) Cell migration and invasion assay in SW480 shNT and shADAR2 cells; n = 3 biological replicates.
(O) Diagram of the ADAR2 self-editing product.
(P) qPCR of ADAR2 self-editing in organoids of WT and PKCz KO mice (left) and SW480 shNT and shPKCz cells (right); n = 3 biological replicates.
(Q) Diagram of ADAR2 domains in relation to PKCz phosphorylation sites.
(R) In vitro phosphorylation of GST-ADAR2WT and GST-ADAR2SS211/216AA; n = 2 biological replicates.
(S) qPCR ofmiR-200s (left) and immunoblot of Flag-ADAR2 (right) in SW480 cells stably expressing ADAR2 WT, ADAR2SS211/216AA, or ADAR2E396A; n = 3 biological
replicates.
(T) Sanger sequencing results for COPAI164V editing in SW480 and SW620 cells (left), calibration curve of editing frequency (middle), and quantification of the
editing frequency (right); n = 3 biological replicates.
Results are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. See also Figure S4.
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ADAR2 is regulated by PKCz is extremely important because it
identifies a synthetic vulnerability of PKCz-deficient tumors.
In this study, we also show that COPA, a previously identified
substrate of ADAR2, is hypo-edited in CRC cells deficient for
PKCz, which further confirms the functional role of the PKCz-
ADAR2 connection. Interestingly, COPA has also been reported
to be hypo-edited in multiple types of cancers (Chan et al., 2014,
2016; Han et al., 2015), which suggests that the editing of COPA
may have a functional role in modulating tumor growth. COPA is
part of the coat protein I (COPI) complex, which has been shown
to mediate the retrieval of proteins from the Golgi back to the
endoplasmic reticulum (ER) (Letourneur et al., 1994). This is
noteworthy, because the ER has been reported to be the site
of RISC formation and mRNA silencing, whereas the Golgi lies
on the exit route from the ER to the secretory and endosomal
pathways. These pathways have been implicated in RISC
turnover as well as miRNA secretion (Gibbings et al., 2009; Lee
et al., 2009; Stalder et al., 2013). Therefore, it is tempting to spec-
ulate that COPA editing may have a role in preventing the secre-
tion of the miR-200s, although other substrates might also be
important mediators of the functional consequence of losing
the PKCz/ADAR2 axis. In this regard, this study opens the impor-
tant question of how the editing activity of ADAR2 regulates the
secretion of miR-200s. One possibility could be through direct
editing of miR-200 itself. However, we did not find changes in
editing in miR-200s upon PKCz deficiency in our system (not
shown). Alternatively, ADAR2 editing could be impacting the
levels of RNA-binding proteins or other components of the
miRNA secretion machinery or competing endogenous RNAs.
Therefore, the identification of the ADAR2 substrates mediating
the selective secretion ofmiR-200 deserves further investigation,
and will contribute to a better understanding of the mechanisms
of miRNA secretion and the selective loading of miRNAs in
extracellular vesicles.
Our finding that PKCz deficiency promotes the circulation of
miR-200s is of great significance, not only as a mechanism to
downregulate their intracellular levels in the tumor cell but
also because EVs and their miRNA content are being increas-
ingly accepted as vehicles to promote metastasis (Becker
et al., 2016). Similarly, the paracrine action of miR-200 secre-
tion could allow the transition of the fibroblasts in the metas-
tasis niche into cancer-associated fibroblasts (CAFs), which
may increase the stromal response. This potential effect is
highly pertinent, considering that an activated stroma is
increasingly appreciated in CRC patients as a marker of poor
prognosis and increased metastasis (Calon et al., 2015; Guin-
ney et al., 2015; Isella et al., 2015). Altogether, the results re-
ported here highlight the importance of identifying actionable
signaling vulnerabilities unleashed upon the inactivation of tu-
mor suppressors and establish PKCz-derived signals control-
ling miR-200s as potentially important therapeutic targets in
cancer metastasis.
EXPERIMENTAL PROCEDURES
A detailed description of the experimental procedures utilized in this work
can be found in Supplemental Experimental Procedures. Primers used are
described in Table S2.
Mice
PKCz/, APCMin/+, Lgr5-EGFP-ires-creERT2 (Lgr5), Lgr5;PKCzf/f, Lgr5;APCf/f,
and Lgr5;APCf/f;PKCzf/fmicewere described previously (Llado et al., 2015). For
the intestinal regeneration experiments, mice were handled as described pre-
viously (Llado et al., 2015). For specific ablation of PKCz in Lgr5+ cells, 8-week-
oldmicewere treated as described previously (Llado et al., 2015). Experimental
mice were all males and aged 8 weeks (PKCz/) or 5–8 weeks (NOD scid
gamma [NSG]) at the time of experimentation. NSGmice were randomized be-
tween litters to prevent a bias toward age. Animal handling and experimental
procedures were approved by the Sanford Burnham Prebys (SBP) Institutional
Animal Care and Use Committee.
Patient Samples
Blood samples were collected in EDTA tubes (9 mL) immediately before sur-
gery. Samples were centrifuged at 1,8003 g for 10min. Plasmawas collected,
subjected to a second centrifugation at 3,000 3 g for 10 min, aliquoted, and
stored at80C until analysis. All donors were informed of the aim of the study
and gave consent to donate their samples. Corresponding clinical data were
obtained from medical records and de-identified. The study was approved
by the Ethics and Health Research Committee of Fundacio´n Jime´nez Dı´az
University Hospital (CEIC-FJD).
Statistical Analysis
The significance level for statistical testing was set at p <0.05. For the animal
studies, we used G*Power Data (Faul et al., 2007) analysis to ensure adequate
power to detect a prespecified effect size. Specifically, a 2-sided t test with
a sample size of 8 mice per group achieves approximately 80% power at
a 2-tailed 0.05 significance level. No statistical method was used to predeter-
mine any other sample sizes.
DATA AND SOFTWARE AVAILABILITY
The accession number for the microarray data reported in this paper is GEO:
GSE42186. All original, unprocessed data can be accessed at Mendeley Data
(https://doi.org/10.17632/9wcwrfn7yh.2).
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